Prosecution Insights
Prosecution Insights
7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 17 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (29%) |
| §102 only | 1 (14%) |
| No statute on record | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, ANDREW D | 1 | 42.1% | +31.4% |
| SHIAO, REI TSANG | 1 | 80.0% | -34.5% |
| ALLEN, MICHAEL D | 1 | 32.6% | +48.7% |
| MCDOWELL, BRIAN E | 1 | 74.3% | +30.6% |
| RONEY, CELESTE A | 1 | 62.3% | +18.0% |
| FAY, ZOHREH ALEMZADEH | 1 | 51.8% | -6.7% |
| KAUFMAN, CLAIRE M | 1 | 62.8% | +51.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18230392 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | MCDOWELL, BRIAN E | 97d overdue |
| 18024459 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | RONEY, CELESTE A | 5d overdue |
| 18278876 | METHOD FOR DETECTING AND QUANTIFYING NUCLEIC ACID FROM ENVIRONMENTAL SAMPLES | ALLEN, MICHAEL D | 2d overdue |
| 18014097 | COMBINED USE OF ANTI-CCR8 ANTIBODY AND CHEMOTHERAPEUTIC AGENT | KAUFMAN, CLAIRE M | 30d |
| 18578932 | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | KOSAR, ANDREW D | 84d |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1691 | 1 |
| 1671 | 1 |
| 1624 | 1 |
| 1612 | 1 |
| 1617 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578932 | NITROGEN-CONTAINING TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | KOSAR, ANDREW D | 1625 | — | Final Rejection | 84d | Pending | Aug 22, 2024 |
| 18525177 | TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A COMPLICATION RISK FACTOR | SHIAO, REI TSANG | 1691 | Other | Non-Final OA | 30d overdue | Pending | Nov 30, 2023 |
| 18278876 | METHOD FOR DETECTING AND QUANTIFYING NUCLEIC ACID FROM ENVIRONMENTAL SAMPLES | ALLEN, MICHAEL D | 1671 | §103 | Non-Final OA | 2d overdue | Pending | Aug 25, 2023 |
| 18230392 | SUBSTITUTED POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVE PRODRUG | MCDOWELL, BRIAN E | 1624 | — | Final Rejection | 97d overdue | Pending | Aug 04, 2023 |
| 18024459 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | RONEY, CELESTE A | 1612 | §103 | Non-Final OA | 5d overdue | Pending | Mar 02, 2023 |
| 18007119 | LYOPHILIZED FORMULATION CONTAINING CEPHALOSPORIN HAVING CATECHOL GROUP AND THE MANUFACTURING METHOD | FAY, ZOHREH ALEMZADEH | 1617 | Other | Final Rejection | 27d | Pending | Jan 27, 2023 |
| 18014097 | COMBINED USE OF ANTI-CCR8 ANTIBODY AND CHEMOTHERAPEUTIC AGENT | KAUFMAN, CLAIRE M | 1674 | §102 | Non-Final OA | 30d | Pending | Dec 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial